Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

In evaluating whether Bristol Myers Squibb Co. (NYSE:BMY) or Novo Nordisk A/S (NYSE:NVO) presents a more promising investment opportunity for 2026, investors must weigh the strengths and challenges of each healthcare giant.

Bristol Myers Squibb operates as a diversified biopharmaceutical leader, with a substantial portfolio centered on oncology, hematology, and neuroscience. The company's flagship products, such as Eliquis and Opdivo, generate significant revenue streams. However, Bristol Myers Squibb recently terminated a manufacturing agreement with Cellares in August 2026, signaling a potential disruption in its supply chain. Despite this setback, the firm remains focused on maintaining its leadership in high-demand therapeutic areas.

On the other hand, Novo Nordisk has established itself as a household name through its dominance in the obesity and diabetes markets. The company's innovative approach to tackling these prevalent health issues positions it favorably for long-term growth. With a strong emphasis on expanding its presence in these critical sectors, Novo Nordisk presents a compelling case for investors seeking exposure to the healthcare industry's most promising opportunities.

As investors navigate the shifting regulatory landscapes faced by both companies, a data-driven comparison becomes essential. Bristol Myers Squibb's recent manufacturing agreement termination and Novo Nordisk's continued focus on high-potential therapeutic areas both warrant careful consideration. Ultimately, the choice between these two healthcare titans will depend on investors' appetite for stability versus growth potential in the healthcare sector by 2026.